Fundraising Fox

Io Therapeutics

Spring, US · Founded 2010 · Texas corporation

Io Therapeutics develops small molecule retinoid drugs, including IRX4204 and IRX5183, as potential treatments for oncology, neurologic, autoimmune, and dermatologic conditions such as psoriasis. It is a biopharmaceutical company focused on clinical-stage therapeutic product development.

BiotechHealthtech

Founders & leadership

Io Therapeutics was founded in 2010 by Roshantha A. Chandraratna and Rosh Chandraratna.

RA
Roshantha A. ChandraratnaCo-founder
RC
Rosh ChandraratnaCo-founder, initial President & Chief Scientific Officer
SL
Sharon LewNamed on SEC filing
SC
Sahani ChandraratnaNamed on SEC filing
VV
Vidyasagar VuligondaCo-founder, Director & Chief Science Officer
MS
Martin SandersCo-founder, Executive Chairman & CEO

Board

ST
Scott ThacherBoard director

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 2 rounds · 2013–2023

▶$4.2MraisedAug 2023 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sharon LewExecutive Officer
  • Sahani ChandraratnaDirector
  • Vidyasagar VuligondaExecutive Officer
  • Martin SandersExecutive Officer
Offering amount
$4.2M
Amount sold
$4.2M
First sale
Feb 2023
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$443.5KraisedJan 2014 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott ThacherDirector
  • Martin E. SandersExecutive Officer, Director
  • Roshantha A. ChandraratnaExecutive Officer, Director
Offering amount
$1M
Amount sold
$443.5K
First sale
Dec 2013
Incorporated
Corporation, California, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
IO Biotech12 shared keywordsIOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
Iovance10 shared keywordsIovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.
iBio8 shared keywordsiBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
Elicio8 shared keywordsElicio Therapeutics is a biopharmaceutical company focused on developing therapeutic treatments.
MD Anderson Cancer Center7 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.

Companies competing with Io Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Io Therapeutics do?
Io Therapeutics develops small molecule retinoid drugs, including IRX4204 and IRX5183, as potential treatments for oncology, neurologic, autoimmune, and dermatologic conditions such as psoriasis. It is a biopharmaceutical company focused on clinical-stage therapeutic product development.
Who founded Io Therapeutics?
Io Therapeutics was founded by Roshantha A. Chandraratna, Rosh Chandraratna in 2010.
How much funding has Io Therapeutics raised?
Io Therapeutics has disclosed $4.6M raised across 2 rounds.
Where is Io Therapeutics headquartered?
Io Therapeutics is headquartered in Spring, US.